Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

Ansell (ASX:ANN): FY26 Protective Products and Operating Priorities

Ansell Limited (ASX:ANN) operates through healthcare protection and industrial safety product lines. These activities carry distinct commercial characteristics, including variations in customer contracts, productSupplyrequirements and the timing ofRevenuerecognition. Assessing the business therefore involves more than a headline sales figure: segment disclosures, operating costs and …

Aditi Sarkar | 03 November 2026

Telix Pharmaceuticals (ASX:TLX): Q3 2026 Imaging Revenue and Pipeline Milestones

Telix Pharmaceuticals Limited (ASX:TLX) operates through Precision Medicine products and therapeutic radiopharmaceutical programmes. These activities carry distinct commercial characteristics, including variations in customer contracts, productSupplyrequirements and the timing of revenue recognition. Assessing the business therefore involves more than a headline sales figure: segment disclosures, …

Aditi Sarkar | 03 November 2026

EBOS Group Limited (ASX:EBO): 2026 Results, Operations and Key Developments

The core activities of EBOS Group Limited (ASX:EBO) involve distribution of pharmaceutical, medical, healthcare and animal care products across Australasia. The company’s operating model must be assessed against the type of products or services delivered, the customers involved and the expenditure needed to support …

Aditi Sarkar | 03 November 2026

Mesoblast Limited (ASX:MSB): 2026 Results, Operations and Key Developments

The core activities of Mesoblast Limited (ASX:MSB) involve development and commercialisation of allogeneic cellular medicines for inflammatory diseases. The company’s operating model must be assessed against the type of products or services delivered, the customers involved and the expenditure needed to support them. In …

Aditi Sarkar | 03 November 2026

Neuren Pharmaceuticals Limited (ASX:NEU): 2026 Results, Operations and Key Developments

The core activities of Neuren Pharmaceuticals Limited (ASX:NEU) involve development of neurological treatments and receipt of DAYBUE trofinetide royalties. The company’s operating model must be assessed against the type of products or services delivered, the customers involved and the expenditure needed to support them. …

Aditi Sarkar | 03 November 2026

PYC Therapeutics Limited (ASX:PYC): 2026 Results, Operations and Key Developments

The core activities of PYC Therapeutics Limited (ASX:PYC) involve development of peptide-linked RNA therapeutics for inherited genetic diseases. The company’s operating model must be assessed against the type of products or services delivered, the customers involved and the expenditure needed to support them. In …

Aditi Sarkar | 03 November 2026

Regis Healthcare Limited (ASX:REG): 2026 Results, Operations and Key Developments

The core activities of Regis Healthcare Limited (ASX:REG) involve residential aged care services including accommodation, nursing and resident care across Australia. The company’s operating model must be assessed against the type of products or services delivered, the customers involved and the expenditure needed to …

Aditi Sarkar | 03 November 2026

4DMedical Limited (ASX:4DX): 2026 Results, Operations and Key Developments

The core activities of 4DMedical Limited (ASX:4DX) involve development of software for respiratory imaging and assessment of regional lung function. The company’s operating model must be assessed against the type of products or services delivered, the customers involved and the expenditure needed to support …

Aditi Sarkar | 03 November 2026

Nanosonics Limited (ASX:NAN): 2026 Results, Operations and Key Developments

The core activities of Nanosonics Limited (ASX:NAN) involve development of infection-prevention technology including trophon systems for ultrasound probe disinfection. The company’s operating model must be assessed against the type of products or services delivered, the customers involved and the expenditure needed to support them. …

Aditi Sarkar | 03 November 2026

Integral Diagnostics Limited (ASX:IDX): 2026 Results, Operations and Key Developments

The core activities of Integral Diagnostics Limited (ASX:IDX) involve provision of diagnostic imaging services through clinics in Australia and New Zealand. The company’s operating model must be assessed against the type of products or services delivered, the customers involved and the expenditure needed to …

Aditi Sarkar | 03 November 2026
Support

Hi! How can we help you today?

Loading…